Home » Stocks » Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. (ORMP)

Stock Price: $2.60 USD -0.19 (-6.81%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $2.50 -0.10 (-3.85%) Oct 21, 7:02 PM

Stock Price Chart

Key Info

Market Cap 61.17M
Revenue (ttm) 2.71M
Net Income (ttm) -10.80M
Shares Out 23.53M
EPS (ttm) -0.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $2.60
Previous Close $2.79
Change ($) -0.19
Change (%) -6.81%
Day's Open 2.84
Day's Range 2.56 - 2.84
Day's Volume 68,414
52-Week Range 2.32 - 6.05

More Stats

Market Cap 61.17M
Enterprise Value 20.43M
Earnings Date (est) Jan 13, 2021
Ex-Dividend Date n/a
Shares Outstanding 23.53M
Float 19.32M
EPS (basic) -0.59
EPS (diluted) -0.57
FCF / Share -0.57
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 176,036
Short Ratio 0.79
Short % of Float 0.91%
Beta 1.58
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 22.57
PB Ratio 1.85
Revenue 2.71M
Operating Income -11.09M
Net Income -10.80M
Free Cash Flow -13.25M
Net Cash 40.74M
Net Cash / Share 1.73
Gross Margin 96.42%
Operating Margin -409.04%
Profit Margin -398.30%
FCF Margin -489.08%
ROA -16.58%
ROE -38.78%
ROIC -40.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(271.92% upside)
Current: $2.60
Target: 9.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth10.37%-0.29%283.15%-------
Gross Profit2.612.542.270.15------
Operating Income-14.63-13.53-10.77-10.01-7.38-5.91-4.30-2.88-2.44-2.97
Net Income-14.36-12.73-10.48-10.96-7.23-5.70-4.23-3.34-1.56-2.98
Shares Outstanding17.4514.8813.3112.6210.829.247.215.885.424.78
Earnings Per Share-0.82-0.86-0.79-0.87-0.67-0.62-0.59-0.57-0.24-0.60
Operating Cash Flow-12.94-14.66-5.834.66-4.95-4.07-3.40-2.30-1.71-1.42
Capital Expenditures-0.02-0.01-0.01-0.01--0.01-0.01---
Free Cash Flow-12.96-14.66-5.844.65-4.95-4.08-3.40-2.30-1.71-1.42
Cash & Equivalents32.2830.4620.1431.0317.2521.318.495.103.721.32
Net Cash / Debt32.2830.4620.1431.0317.2521.318.495.103.721.32
Book Value19.3931.1119.2426.1924.8320.798.133.783.720.83
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Oramed Pharmaceuticals Inc.
Country United States
CEO Nadav Kidron

Stock Information

Ticker Symbol ORMP
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ORMP


Oramed Pharmaceuticals engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, which completed phase II clinical trials is an orally ingestible insulin capsule for the treatment of diabetes; and ORMD-0901 that completed phase I clinical trials is an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes. It is also developing a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.